sumatriptan has been researched along with Recrudescence in 97 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Successfully screened adult migraineurs who returned baseline diaries showing 2 to 7 migraine attacks monthly and < 15 headache and/or neck pain days/month received blister packs containing 3 sumatriptan/naproxen/1 placebo for treatment of 4 migraines." | 9.19 | Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it? ( Calhoun, AH; Ford, S, 2014) |
| "To study the efficacy and practicality of treating headache in professional footballers with intranasal sumatriptan." | 7.73 | Open label study of intranasal sumatriptan (Imigran) for footballer's headache. ( Heywood, J; McCrory, P; Ugoni, A, 2005) |
| "To demonstrate that sumatriptan may induce activation or aggravation of pain at sites of inflammation caused by trauma or disease." | 7.72 | Activation of pain by sumatriptan. ( Clark, DW; Coulter, DM; Passier, JL; van Puijenbroek, EP, 2003) |
| "To document the relationship between the 5-HT receptor agonist sumatriptan and a change in the nature of cluster headache in four cases." | 7.70 | Alteration in nature of cluster headache during subcutaneous administration of sumatriptan. ( Hering-Hanit, R, 2000) |
| "To describe a patient with cyclic vomiting who was treated successfully with sumatriptan, a serotonin, agonist." | 7.69 | Sumatriptan in the treatment of cyclic vomiting. ( Benson, JM; Book, LS; Zorn, SL, 1995) |
| "Headache recurrence (HR) is the major limitation of sumatriptan in the acute treatment of migraine attacks." | 7.69 | Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. ( de Vriend, RH; Ferrari, MD; Jaspers, NM; Visser, WH, 1996) |
| "Successfully screened adult migraineurs who returned baseline diaries showing 2 to 7 migraine attacks monthly and < 15 headache and/or neck pain days/month received blister packs containing 3 sumatriptan/naproxen/1 placebo for treatment of 4 migraines." | 5.19 | Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it? ( Calhoun, AH; Ford, S, 2014) |
| "In order to investigate the plausible association of migraine recurrence with anxiety and depressive symptoms, a multicentre, randomized, double-blind, placebo-controlled, crossover clinical trial was conducted using sumatriptan as a vehicle drug." | 5.14 | Migraine recurrence is not associated with depressive or anxiety symptoms. Results of a randomized controlled trial. ( Charmoussi, S; Doitsini, S; Georgiadis, G; Kodounis, A; Mitsikostas, DD; Thomas, A; Vikelis, M; Xifaras, M; Zaglis, D, 2010) |
| "To study the efficacy and practicality of treating headache in professional footballers with intranasal sumatriptan." | 3.73 | Open label study of intranasal sumatriptan (Imigran) for footballer's headache. ( Heywood, J; McCrory, P; Ugoni, A, 2005) |
| "To demonstrate that sumatriptan may induce activation or aggravation of pain at sites of inflammation caused by trauma or disease." | 3.72 | Activation of pain by sumatriptan. ( Clark, DW; Coulter, DM; Passier, JL; van Puijenbroek, EP, 2003) |
| "To document the relationship between the 5-HT receptor agonist sumatriptan and a change in the nature of cluster headache in four cases." | 3.70 | Alteration in nature of cluster headache during subcutaneous administration of sumatriptan. ( Hering-Hanit, R, 2000) |
| "To describe a patient with cyclic vomiting who was treated successfully with sumatriptan, a serotonin, agonist." | 3.69 | Sumatriptan in the treatment of cyclic vomiting. ( Benson, JM; Book, LS; Zorn, SL, 1995) |
| "Headache recurrence (HR) is the major limitation of sumatriptan in the acute treatment of migraine attacks." | 3.69 | Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. ( de Vriend, RH; Ferrari, MD; Jaspers, NM; Visser, WH, 1996) |
| "Migraine is a common and incapacitating neurologic disorder manifesting with episodic moderate to a severe headache and other symptoms such as photophobia, phonophobia, nausea, and vomiting." | 2.80 | Intravenous Valproate versus Subcutaneous Sumatriptan in Acute Migraine Attack. ( Ghaderibarmi, F; Tavakkoli, N; Togha, M, 2015) |
| "Triptan's efficacy in the treatment of migraine has never been reported in Taiwanese." | 2.73 | Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine. ( Fuh, JL; Wang, SJ; Wu, ZA, 2007) |
| "In this double-blind, double-dummy, randomised, parallel group, multicentre study, the efficacy of dosing and re-dosing of a fixed combination of indomethacin, prochlorperazine and caffeine (Indoprocaf) was compared with encapsulated sumatriptan in the acute treatment of two migraine attacks." | 2.73 | Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, mu ( Cerbo, R; Del Bene, E; Ferrari, A; Genco, S; Grazioli, I; Martelletti, P; Nappi, G; Pinessi, L; Sandrini, G; Sarchielli, P; Tamburro, P; Uslenghi, C; Zanchin, G, 2007) |
| "One hundred twelve patients with migraine with or without aura according to the diagnostic criteria of the International Headache Society were randomized to treat 2 migraine attacks with a fixed combination of indomethacin, prochlorperazine, and caffeine and 2 migraine attacks with sumatriptan." | 2.71 | Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial. ( Aloisio, A; Del Bianco, P; Di Monda, V; Fonzari, M; Grazioli, I; Nicolodi, M; Sicuteri, F; Uslenghi, C; Vecchiet, L, 2003) |
| "Zolmitriptan nasal spray was also significantly superior to placebo for headache response at 4 hours, sustained headache response at 24 hours and sustained pain-free rate at 24 hours." | 2.71 | Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. ( Brandes, J; Dodick, D; Elkind, A; Mathew, N; Rodichok, L, 2005) |
| "Almotriptan is a novel and specific serotonin 5-HT1B/1D agonist for the acute treatment of migraine." | 2.70 | Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. ( Cabarrocas, X; Dowson, AJ; Laínez, JM; Massiou, H, 2002) |
| "As part of the stratified treatment of migraine, those patients whose headaches are mild or moderate may benefit from nontriptan medications." | 2.70 | Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. ( Cady, R; DiSerio, F; Elkind, A; Freitag, FG; Gallagher, RM; Goldstein, J; Klapper, JA; Rapoport, AM; Sadowsky, C; Saper, JR; Smith, TR, 2001) |
| " Compared with the 25 mg dose, the 100 mg and 50 mg doses were significantly more likely to provide headache relief at 2, 3, and 4 h after dosing and complete headache resolution at 3 and 4 h after dosing (P < 0." | 2.69 | Patient preference for oral sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: a double-blind, randomized, crossover study. Sumatriptan Tablets S2CM11 Study Group. ( Ashford, EA; Gibbs, M; Hassani, H; Salonen, R, 1999) |
| "Zolmitriptan, 2." | 2.69 | A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. ( Chitra, R; Dennish, G; Gallagher, RM; Spierings, EL, 2000) |
| ") In a subset of patients experiencing headache relief after 2 attacks, headache recurrence 4 to 24 hours after initial dosing was reported by 55 naratriptan- and 77 sumatriptan-treated patients (41% and 57%, respectively; P = 0." | 2.69 | Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group. ( Becker, W; Boswell, D; Crisp, A; Göbel, H; Hauge, T; Mihout, B; Niewold, J; Tørring, J; Winter, P, 2000) |
| " Headache response 2 hours after dosing was reported by 76% of patients taking the 10-mg dose and 72% of those taking the 20-mg dose." | 2.69 | One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study. ( Asgharnejad, M; Austin, R; Laurenza, A; Nett, R; Peykamian, M; Rothner, AD; Winner, P, 2000) |
| "Oral sumatriptan was similarly effective at relieving the associated symptoms and at reducing clinical disability in most attacks." | 2.69 | Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks. ( Benassuti, C; Bussone, G; Cortelli, P; Fabbri, L; Manzoni, GC; Roncolato, M, 2000) |
| "Sumatriptan (all doses) was similarly effective at relieving nausea and photophobia or phonophobia or both and at reducing clinical disability." | 2.69 | Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. ( Cunin, G; Pfaffenrath, V; Prendergast, S; Sjonell, G, 1998) |
| "Mean productivity loss 2 hours after dosing and across the work shift; percentages of patients returning to normal work performance within 2 hours after dosing and across the work shift; percentages of patients experiencing headache relief (reduction of moderate or severe predose pain to mild or no pain) 1 and 2 hours after dosing." | 2.69 | Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. ( Cady, RC; Jhingran, P; O'Quinn, S; Pait, DG; Ryan, R, 1998) |
| "Sumatriptan nasal spray was well tolerated, the incidence of adverse events with each dose of sumatriptan being similar to the placebo (20-27 and 23%, respectively)." | 2.69 | Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine. ( Ashford, EA; Becker, WJ; Dahlof, C; Hassani, H; Peikert, A; Salonen, RJ, 1999) |
| " Sumatriptan is more effective, but resulted in more adverse events." | 2.69 | Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG St ( Diener, HC, 1999) |
| "Eletriptan is a potent and selective agonist at human recombinant 5HT1B/1D receptors, with efficacy in animal models that predict antimigraine activity." | 2.69 | Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. ( Ferrari, MD; Goadsby, PJ; Jackson, NC; Olesen, J; Poole, PH; Senard, JM; Stovner, LJ, 2000) |
| "Oral sumatriptan 50 mg has been found to have good efficacy and tolerability in the acute treatment of migraine but has been less well studied than the 100 mg dose." | 2.69 | A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine. Sumatriptan Tablets S2CM07 Study Group. ( Ashford, EA; Brautaset, NJ; Hassani, H; Reunanen, M; Saiers, J; Savani, N; Szirmai, I, 1999) |
| " We studied whether pharmacokinetic or pharmacodynamic differences may explain these different clinical effects." | 2.68 | Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. ( Burggraaf, J; Cohen, AF; Ferrari, MD; Fowler, PA; Muller, LM; Schoemaker, RC; Visser, WH, 1996) |
| "5 mg dose was on the shoulder of the dose-response curve (2-h headache response rate 64%), showing similar efficacy to the 5 mg dose (67%)." | 2.68 | Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. ( Sawyer, J; Schoenen, J, 1997) |
| "Median time to recurrence was shorter after subcutaneous (12." | 2.68 | Oral and subcutaneous sumatriptan in the acute treatment of migraine: an open randomized cross-over study. ( Carpay, HA; Matthijsse, P; Mulder, PG; Steinbuch, M, 1997) |
| "Sumatriptan was generally well tolerated." | 2.68 | The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache. ( Cull, RE; Dunbar, A; Price, WH, 1997) |
| "Patients (n = 667) treated up to three migraine attacks in a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial." | 2.68 | Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. ( Alderton, CJ; Cutler, NR; Davis, RL; Ferrari, MD; Paulsgrove, LA; Rapoport, AM; Visser, WH, 1995) |
| "Patients of either sex, with migraine with or without aura, between the ages of 18 and 65 years." | 2.68 | A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. ( Le Force, B; Margul, B; Ricalde, O; Saper, J; Winner, P, 1996) |
| "The efficacy in acute migraine of oral sumatriptan was assessed in a double-blind, randomised, placebo-controlled, crossover study of 61 patients (mean age 39 [SD 10] years)." | 2.67 | Oral sumatriptan in acute migraine. ( Anthony, M; Bladin, PF; Donnan, GA; Goadsby, PJ; Lance, JW; Symington, G; Zagami, AS, 1991) |
| "Sumatriptan was well tolerated, and the frequency and severity of adverse events did not change with repeated administration." | 2.67 | Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. ( Cady, RK; Dexter, J; Markley, H; Osterhaus, JT; Sargent, JD; Webster, CJ, 1993) |
| "A similar number of patients reported migraine recurrence, within 24 h in both treatment groups." | 2.67 | A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group. ( , 1991) |
| "If the migraine had not improved at 1 h, patients had the option of taking a second identical injection." | 2.67 | Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group. ( , 1991) |
| "Sumatriptan was significantly more effective than Cafergot at reducing the intensity of headache from severe or moderate to mild or none; 66% (145/220) of those treated with sumatriptan improved in this way by 2 h, compared with 48% (118/246) of those treated with Cafergot (p less than 0." | 2.67 | A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. ( , 1991) |
| "Sumatriptan was superior to placebo in treating headache recurrence: 74 vs 49% (p = 0." | 2.67 | Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. ( Anderson, BA; Ashford, E; Bates, D; Ferrari, MD; James, MH; Nappi, G; Pilgrim, A, 1994) |
| "Sumatriptan was significantly more effective than placebo in relieving headache (moderate/severe reduced to mild/none) at 2 h (50 vs." | 2.67 | Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group. ( , 1991) |
| "Oral sumatriptan was consistently effective in the treatment of headache recurrence." | 2.67 | Oral sumatriptan in the treatment of recurrent headache. ( Cady, RK; Crummett, D; Littlejohn, TW; Rubino, J, 1994) |
| "The headache in migraine attacks may be caused by dilatation of certain cranial arteries or arteriovenous anastomoses, by neurogenic dural plasma extravasation, or by both of these mechanisms." | 2.67 | Treatment of migraine attacks with sumatriptan. ( , 1991) |
| "The history of recurrence in early sumatriptan randomised clinical trials is described." | 2.45 | What can be learned from the history of recurrence in migraine? A comment. ( Tfelt-Hansen, P, 2009) |
| "The debilitating effect of migraine has fueled the search for more specific agents to treat its characteristic and associated symptoms." | 2.43 | Evaluating the triptans. ( Loder, EW; Mathew, NT, 2005) |
| "The pathophysiology of migraine is complex and involves multiple neurophysiological pathways." | 2.43 | Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach. ( Bigal, ME; Krymchantowski, AV, 2006) |
| "Headache associated with the chronic use of medications has become a significant problem in the management of headache." | 2.43 | [Medication-overuse headache]. ( Katsarava, Z; Rabe, K, 2006) |
| "Frovatriptan has no clinically significant pharmacokinetic interactions with drugs used for migraine prophylaxis or with commonly prescribed medications." | 2.42 | Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. ( Balbisi, EA, 2004) |
| "The treatment of migraine takes into consideration the intensity of the headache and the accompanying symptoms." | 2.42 | [Treatment and prophylaxis of an acute migraine attack]. ( Diener, HC; Gendolla, A, 2004) |
| "Rizatriptan 10 mg was generally superior to sumatriptan on a measure of time-to-pain-relief within 2 h, where pain relief was defined as a reduction of pain to mild or none (odds ratio for rizatriptan versus sumatriptan 100 mg = 1." | 2.41 | Rizatriptan: pharmacological differences from sumatriptan and clinical results. ( Lines, CR; McCarroll, KA; Visser, WH, 2001) |
| "Two new intranasal migraine medications, sumatriptan and dihydroergotamine mesylate, may offer specific advantages for patients who are seeking alternatives to various oral or parenteral migraine abortive therapies." | 2.41 | Newer intranasal migraine medications. ( Logemann, CD; Rankin, LM, 2000) |
| "Recurrence of migraine, long-term usage, and side effects of serotonin1D agonists are included in the review." | 2.40 | Serotonin 1D (5-HT1D) agonists and other agents in acute migraine. ( Mathew, NT, 1997) |
| "Headaches are a common entity in the ambulatory population." | 2.40 | Diagnosis, prophylaxis, and treatment of headaches in the athlete. ( Kaplan, B; Swain, RA, 1997) |
| "About every second (53%) migraineur using subcutaneous sumatriptan reports headache recurrence." | 2.39 | Clinical experiences from Sweden on the use of subcutaneously administered sumatriptan in migraine and cluster headache. ( Dahlöf, C; Ekbom, K; Persson, L, 1994) |
| "Sumatriptan is a potent and selective agonist at a vascular serotonin1 (5-hydroxytryptamine1; 5-HT1) receptor subtype (similar to 5-HT1D) and is used in acute treatment of migraine and cluster headache." | 2.39 | Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. ( McTavish, D; Plosker, GL, 1994) |
| "Three migraine attacks have been studied in 30 patients aged 39." | 1.34 | [Efficacy of sumamigren at early and late stages of migraine attack]. ( Azimova, IuE; Tabeeva, GR, 2007) |
| "9% of the patients withdrew from the study because of insufficient efficacy or adverse events." | 1.30 | Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. ( Göbel, H; Heinze, A; Heinze-Kuhn, K; Lindner, V; Stolze, H, 1999) |
| "We studied the recurrence rate of migraine attacks with the use of sumatriptan plus tolfenamic acid among patients who presented frequent recurrence with sumatriptan." | 1.30 | Tolfenamic acid decreases migraine recurrence when used with sumatriptan. ( Adriano, M; Fernandes, D; Krymchantowski, AV, 1999) |
| "The other two had migraine without aura." | 1.30 | Recurrent neck pain as a variant of migraine: description of four cases. ( Accornero, N; De Marinis, M, 1997) |
| " Overall, the mean percentages of attacks per patient in which headache relief had been obtained 4 h after dosing were 71%, 71%, and 80% for the 25 mg, 50 mg, and 100 mg doses, respectively." | 1.30 | Patient-selected dosing in a six-month open-label study evaluating oral sumatriptan in the acute treatment of migraine. Sumatriptan Tablets S2CM10 Study Group. ( Ashford, EA; Dowson, AJ; Flöter, T; Hassani, H; Prendergast, S; Roberts, GW; Szczudlik, A, 1999) |
| "(1) Zolmitriptan is an antimigraine drug similar to sumatriptan." | 1.30 | Zolmitriptan: new product. Similar to sumatriptan. ( , 1999) |
| "Oral sumatriptan was effective in clinical practice at doses of 25 and 50 mg." | 1.30 | Dosing of oral sumatriptan: a review of our first 104 patients. ( Becker, J; Frizelis, K; Kunkel, RS; Solomon, GD, 1998) |
| "Dihydroergotamine mesylate was also abortive in the few instances when the headache worsened." | 1.30 | Successful treatment of headache related to intravenous immunoglobulin with antimigraine medications. ( Finkel, AG; Howard, JF; Mann, JD, 1998) |
| "Sumatriptan has been shown to be most effective in migraine attacks, but with transient, slight side effects and high rebound attack rates." | 1.30 | Sumatriptan treatment of acute migraine attacks in a Saudi population. ( al Deeb, S; al Kawi, Z; Bohlega, S; Cheung, P; Yaqub, B, 1997) |
| "Treatment with sumatriptan was efficient in 89." | 1.29 | [18 months long-term analysis of effectiveness, safety and tolerance of sumatriptan s.c. in acute therapy of migraine attacks]. ( Christiani, K; Dworschak, M; Göbel, H; Heinze, A; Heuss, D; Lindner, V; Stolze, H, 1996) |
| "The average number of migraine attacks per month was 3." | 1.29 | How does sumatriptan perform in clinical practice? ( Dahlöf, CG, 1995) |
| " The patients described had a high frequency of attacks (more than two per day); therefore, far higher dosage of the drug was taken than commonly used in cluster headache." | 1.29 | Use of high sumatriptan dosages during episodic cluster headache: three clinical cases. ( Albano, O; Attolini, E; Bassi, A; Cassiano, MA; Cavazzuti, L; Centonze, V; Polito, BM; Ricchhetti, G; Sabbà, C, 1996) |
| " We measured long-term use of sumatriptan and within-patient consistency and change over time of headache relief, headache recurrence, and chest symptoms after sumatriptan." | 1.29 | Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. ( de Vriend, RH; Ferrari, MD; Jaspers, MW; Visser, WH, 1996) |
| "Nine percent failed to respond at all." | 1.29 | Subcutaneous sumatriptan in a clinical setting: the first 100 consecutive patients with acute migraine in a tertiary care center. ( Arrowsmith, F; Baskin, S; Rapoport, AM; Sheftell, FD; Siegel, S; Weeks, RE, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 59 (60.82) | 18.2507 |
| 2000's | 35 (36.08) | 29.6817 |
| 2010's | 3 (3.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calhoun, AH | 1 |
| Ford, S | 1 |
| Ghaderibarmi, F | 1 |
| Tavakkoli, N | 1 |
| Togha, M | 1 |
| Tfelt-Hansen, P | 2 |
| Mitsikostas, DD | 1 |
| Vikelis, M | 1 |
| Kodounis, A | 1 |
| Zaglis, D | 1 |
| Xifaras, M | 1 |
| Doitsini, S | 1 |
| Georgiadis, G | 1 |
| Thomas, A | 1 |
| Charmoussi, S | 1 |
| Dowson, AJ | 2 |
| Massiou, H | 1 |
| Laínez, JM | 1 |
| Cabarrocas, X | 1 |
| Lines, CR | 1 |
| McCarroll, KA | 1 |
| Visser, WH | 5 |
| Pascual, J | 2 |
| Carpay, JA | 1 |
| Linssen, WH | 1 |
| Koehler, PJ | 1 |
| Arends, LR | 1 |
| Tiedink, HG | 1 |
| Di Monda, V | 1 |
| Nicolodi, M | 1 |
| Aloisio, A | 1 |
| Del Bianco, P | 1 |
| Fonzari, M | 1 |
| Grazioli, I | 2 |
| Uslenghi, C | 2 |
| Vecchiet, L | 1 |
| Sicuteri, F | 1 |
| Coulter, DM | 1 |
| Passier, JL | 1 |
| Clark, DW | 1 |
| van Puijenbroek, EP | 1 |
| Balbisi, EA | 1 |
| Diener, HC | 3 |
| Gendolla, A | 1 |
| Dodick, D | 1 |
| Brandes, J | 1 |
| Elkind, A | 3 |
| Mathew, N | 1 |
| Rodichok, L | 1 |
| Mathew, NT | 2 |
| Loder, EW | 1 |
| McCrory, P | 1 |
| Heywood, J | 1 |
| Ugoni, A | 1 |
| Gupta, VK | 1 |
| Krymchantowski, AV | 3 |
| Bigal, ME | 1 |
| Rabe, K | 1 |
| Katsarava, Z | 1 |
| Wang, SJ | 1 |
| Fuh, JL | 1 |
| Wu, ZA | 1 |
| Sandrini, G | 1 |
| Cerbo, R | 1 |
| Del Bene, E | 1 |
| Ferrari, A | 1 |
| Genco, S | 1 |
| Martelletti, P | 1 |
| Nappi, G | 2 |
| Pinessi, L | 1 |
| Sarchielli, P | 1 |
| Tamburro, P | 1 |
| Zanchin, G | 1 |
| Tabeeva, GR | 1 |
| Azimova, IuE | 1 |
| Nakazato, Y | 1 |
| Tamura, N | 1 |
| Shimazu, K | 1 |
| Plosker, GL | 1 |
| McTavish, D | 1 |
| Rapoport, AM | 3 |
| Cutler, NR | 1 |
| Alderton, CJ | 1 |
| Paulsgrove, LA | 1 |
| Davis, RL | 2 |
| Ferrari, MD | 7 |
| Akpunonu, BE | 1 |
| Mutgi, AB | 1 |
| Federman, DJ | 1 |
| Volinsky, FG | 1 |
| Brickman, K | 1 |
| Gilbert, C | 1 |
| Asgharnejad, M | 3 |
| LaPorta, LD | 1 |
| James, MH | 1 |
| Bates, D | 1 |
| Pilgrim, A | 1 |
| Ashford, E | 1 |
| Anderson, BA | 1 |
| Dahlöf, C | 5 |
| Ekbom, K | 1 |
| Persson, L | 1 |
| Cady, RK | 2 |
| Rubino, J | 1 |
| Crummett, D | 1 |
| Littlejohn, TW | 1 |
| Anaya Ordóñez, S | 1 |
| Matas Hoces, A | 1 |
| Bateman, DN | 1 |
| Sheftell, FD | 1 |
| Weeks, RE | 1 |
| Siegel, S | 1 |
| Baskin, S | 1 |
| Arrowsmith, F | 1 |
| Dexter, J | 1 |
| Sargent, JD | 1 |
| Markley, H | 1 |
| Osterhaus, JT | 1 |
| Webster, CJ | 1 |
| Graf, WD | 1 |
| Riback, PS | 1 |
| Winner, P | 2 |
| Ricalde, O | 1 |
| Le Force, B | 1 |
| Saper, J | 1 |
| Margul, B | 1 |
| Centonze, V | 1 |
| Polito, BM | 1 |
| Attolini, E | 1 |
| Cassiano, MA | 1 |
| Sabbà, C | 1 |
| Ricchhetti, G | 1 |
| Bassi, A | 1 |
| Cavazzuti, L | 1 |
| Albano, O | 1 |
| de Vriend, RH | 2 |
| Jaspers, MW | 1 |
| Dahlöf, CG | 1 |
| Göbel, H | 3 |
| Stolze, H | 2 |
| Heinze, A | 2 |
| Dworschak, M | 1 |
| Heuss, D | 1 |
| Christiani, K | 1 |
| Lindner, V | 2 |
| Pfaffenrath, V | 3 |
| Jaspers, NM | 1 |
| Benson, JM | 1 |
| Zorn, SL | 1 |
| Book, LS | 1 |
| Burggraaf, J | 1 |
| Muller, LM | 1 |
| Schoemaker, RC | 1 |
| Fowler, PA | 1 |
| Cohen, AF | 1 |
| Scott, RJ | 1 |
| Aitchison, WR | 1 |
| Barker, PR | 1 |
| McLaren, GI | 1 |
| al Deeb, S | 1 |
| al Kawi, Z | 1 |
| Yaqub, B | 1 |
| Bohlega, S | 1 |
| Cheung, P | 1 |
| Cull, RE | 1 |
| Price, WH | 1 |
| Dunbar, A | 1 |
| De Marinis, M | 1 |
| Accornero, N | 1 |
| Carpay, HA | 1 |
| Matthijsse, P | 1 |
| Steinbuch, M | 1 |
| Mulder, PG | 1 |
| Swain, RA | 1 |
| Kaplan, B | 1 |
| Ryan, R | 2 |
| Baker, CC | 1 |
| Mullican, W | 1 |
| DeBussey, S | 1 |
| Schoenen, J | 1 |
| Sawyer, J | 1 |
| Cunin, G | 1 |
| Sjonell, G | 1 |
| Prendergast, S | 2 |
| Cady, RC | 1 |
| Jhingran, P | 1 |
| O'Quinn, S | 1 |
| Pait, DG | 1 |
| MaassenVanDenBrink, A | 1 |
| Vergouwe, MN | 1 |
| Ophoff, RA | 1 |
| Saxena, PR | 1 |
| Frants, RR | 1 |
| Finkel, AG | 1 |
| Howard, JF | 1 |
| Mann, JD | 1 |
| Solomon, GD | 1 |
| Frizelis, K | 1 |
| Becker, J | 1 |
| Kunkel, RS | 1 |
| Peikert, A | 1 |
| Becker, WJ | 1 |
| Ashford, EA | 4 |
| Hassani, H | 4 |
| Salonen, RJ | 1 |
| Adriano, M | 1 |
| Fernandes, D | 1 |
| Millson, D | 1 |
| Tepper, S | 1 |
| Peatfield, RC | 1 |
| Deleu, D | 1 |
| Hanssens, Y | 1 |
| Heinze-Kuhn, K | 1 |
| Goadsby, PJ | 2 |
| Olesen, J | 2 |
| Stovner, LJ | 1 |
| Senard, JM | 1 |
| Jackson, NC | 1 |
| Poole, PH | 1 |
| Logemann, CD | 1 |
| Rankin, LM | 1 |
| Savani, N | 1 |
| Brautaset, NJ | 1 |
| Reunanen, M | 1 |
| Szirmai, I | 1 |
| Saiers, J | 1 |
| Salonen, R | 1 |
| Gibbs, M | 1 |
| Roberts, GW | 1 |
| Flöter, T | 1 |
| Szczudlik, A | 1 |
| Hering-Hanit, R | 1 |
| Gallagher, RM | 2 |
| Dennish, G | 1 |
| Spierings, EL | 1 |
| Chitra, R | 1 |
| Geraud, G | 2 |
| Zupping, R | 1 |
| Sweet, R | 1 |
| Valette, C | 1 |
| Winter, P | 1 |
| Boswell, D | 1 |
| Crisp, A | 1 |
| Becker, W | 1 |
| Hauge, T | 1 |
| Mihout, B | 1 |
| Niewold, J | 1 |
| Tørring, J | 1 |
| Potrebic, S | 1 |
| Raskin, NH | 1 |
| Rothner, AD | 1 |
| Nett, R | 1 |
| Laurenza, A | 1 |
| Austin, R | 1 |
| Peykamian, M | 1 |
| Pradalier, A | 1 |
| Baudesson, G | 1 |
| Vincent, D | 1 |
| Imberty-Campinos, C | 1 |
| Bussone, G | 1 |
| Manzoni, GC | 1 |
| Cortelli, P | 1 |
| Roncolato, M | 1 |
| Fabbri, L | 1 |
| Benassuti, C | 1 |
| Freitag, FG | 1 |
| Cady, R | 1 |
| DiSerio, F | 1 |
| Goldstein, J | 1 |
| Klapper, JA | 1 |
| Sadowsky, C | 1 |
| Saper, JR | 1 |
| Smith, TR | 1 |
| Gruffyd-Jones, K | 1 |
| Kies, B | 1 |
| Middleton, A | 1 |
| Mulder, LJ | 1 |
| Røsjø , Ø | 1 |
| Millson, DS | 1 |
| Blau, JN | 1 |
| Lloyd, DK | 1 |
| Pilgrim, AJ | 1 |
| Zagami, AS | 1 |
| Donnan, GA | 1 |
| Symington, G | 1 |
| Anthony, M | 1 |
| Bladin, PF | 1 |
| Lance, JW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Full-Factorial, Parallel-Group Study Evaluating Safety and Efficacy of Naltrexone-Acetaminophen Combination in Acute Migraine Treatment in Adults, With Exploratory Focus on Co-Occurring[NCT05685225] | Phase 2 | 300 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for sumatriptan and Recrudescence
| Article | Year |
|---|---|
What can be learned from the history of recurrence in migraine? A comment.
Topics: Clinical Trials as Topic; Humans; Migraine Disorders; Recurrence; Sumatriptan; Vasoconstrictor Agent | 2009 |
Rizatriptan: pharmacological differences from sumatriptan and clinical results.
Topics: Administration, Oral; Humans; Migraine Disorders; Patient Satisfaction; Recurrence; Serotonin Recept | 2001 |
Almotriptan: pharmacological differences and clinical results.
Topics: Administration, Oral; Humans; Indoles; Migraine Disorders; Recurrence; Serotonin Receptor Agonists; | 2001 |
Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine.
Topics: Carbazoles; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Menstruatio | 2004 |
[Treatment and prophylaxis of an acute migraine attack].
Topics: Acupuncture Therapy; Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Analgesics; A | 2004 |
Evaluating the triptans.
Topics: Administration, Oral; Clinical Trials as Topic; Humans; Migraine Disorders; Patient Satisfaction; Pr | 2005 |
Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Drug Therapy, Com | 2006 |
[Medication-overuse headache].
Topics: Acute Disease; Analgesics; Analgesics, Non-Narcotic; Chronic Disease; Ergotamine; Female; Headache; | 2006 |
Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache.
Topics: Administration, Oral; Animals; Cluster Headache; Humans; Injections, Subcutaneous; Migraine Disorder | 1994 |
Clinical experiences from Sweden on the use of subcutaneously administered sumatriptan in migraine and cluster headache.
Topics: Cardiovascular Diseases; Central Nervous System Diseases; Cluster Headache; Humans; Injections, Subc | 1994 |
Sumatriptan.
Topics: Administration, Oral; Clinical Trials as Topic; Humans; Indoles; Injections, Subcutaneous; Migraine | 1993 |
Pharmacologic treatment of recurrent pediatric headache.
Topics: Acetaminophen; Adolescent; Adrenal Cortex Hormones; Analgesics; Aspirin; Child; Child, Preschool; Er | 1995 |
Serotonin 1D (5-HT1D) agonists and other agents in acute migraine.
Topics: Acute Disease; Analgesics, Non-Narcotic; Cluster Headache; Dihydroergotamine; Drug Interactions; Hum | 1997 |
Diagnosis, prophylaxis, and treatment of headaches in the athlete.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Tricyclic; | 1997 |
Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
Topics: Acute Disease; Animals; Clinical Trials as Topic; Coronary Circulation; Coronary Vasospasm; Drug Des | 1999 |
Newer intranasal migraine medications.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Non-Narcotic; Clinical Trials as Topic | 2000 |
New abortive agents for the treatment of migraine.
Topics: Clinical Trials as Topic; Female; Humans; Indoles; Male; Migraine Disorders; Oxazolidinones; Piperid | 2001 |
[Treatment of cluster headache].
Topics: Anti-Inflammatory Agents; Calcium Channel Blockers; Chronic Disease; Cluster Headache; Combined Moda | 2001 |
46 trials available for sumatriptan and Recrudescence
| Article | Year |
|---|---|
Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Double-Blind Method; Drug Admini | 2014 |
Intravenous Valproate versus Subcutaneous Sumatriptan in Acute Migraine Attack.
Topics: Adult; Female; Humans; Male; Middle Aged; Migraine Disorders; Nausea; Recurrence; Sumatriptan; Valpr | 2015 |
Migraine recurrence is not associated with depressive or anxiety symptoms. Results of a randomized controlled trial.
Topics: Adult; Anxiety; Cross-Over Studies; Depression; Double-Blind Method; Female; Humans; Male; Middle Ag | 2010 |
Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Indoles; Male; M | 2002 |
Efficacy of sumatriptan nasal spray in recurrent migrainous headache: an open prospective study.
Topics: Administration, Inhalation; Adult; Female; Headache Disorders; Humans; Male; Migraine Disorders; Pro | 2003 |
Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Caffeine; Central Nervou | 2003 |
Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Double-Blind Method; Drug Tolerance; Female; Hu | 2005 |
Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Midd | 2007 |
Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, mu
Topics: Administration, Oral; Adolescent; Adult; Analgesics; Caffeine; Double-Blind Method; Drug Combination | 2007 |
Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; | 1995 |
Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Double-Blind Method; Emergency Service, Hospital; | 1995 |
Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences.
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male | 1994 |
Oral sumatriptan in the treatment of recurrent headache.
Topics: Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Injections, Subc | 1994 |
[Sumatriptan in the treatment of acute migraine: its role in primary health care].
Topics: Acute Disease; Administration, Oral; Algorithms; Aspirin; Caffeine; Double-Blind Method; Drug Therap | 1994 |
Efficacy of subcutaneous sumatriptan in repeated episodes of migraine.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Indoles; Injections, Subcutaneous; Mal | 1993 |
A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.
Topics: Acute Disease; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Dihydroergotamine; Double-Blind Me | 1996 |
Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response.
Topics: Adolescent; Adult; Aged; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Mig | 1996 |
Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Drug Administrati | 1996 |
The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache.
Topics: Adolescent; Adult; Age of Onset; Aged; Double-Blind Method; Female; Humans; Injections, Subcutaneous | 1997 |
Oral and subcutaneous sumatriptan in the acute treatment of migraine: an open randomized cross-over study.
Topics: Administration, Oral; Adult; Cross-Over Studies; Female; Humans; Injections, Subcutaneous; Male; Mid | 1997 |
Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies.
Topics: Acute Disease; Administration, Intranasal; Adolescent; Adult; Aged; Disability Evaluation; Double-Bl | 1997 |
Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy.
Topics: Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Female; Humans; Menstruation; Midd | 1997 |
Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male | 1998 |
Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial.
Topics: Adult; Double-Blind Method; Efficiency; Female; Humans; Male; Migraine Disorders; Recurrence; Self A | 1998 |
Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine.
Topics: Adult; Aerosols; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart; Humans; Hyper | 1999 |
Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG St
Topics: Adult; Analgesics; Aspirin; Double-Blind Method; Female; Humans; Infusions, Intravenous; Injections, | 1999 |
Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.
Topics: Acute Disease; Administration, Oral; Adult; Double-Blind Method; Female; Humans; Indoles; Male; Midd | 2000 |
A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine. Sumatriptan Tablets S2CM07 Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migr | 1999 |
Patient preference for oral sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: a double-blind, randomized, crossover study. Sumatriptan Tablets S2CM11 Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Metho | 1999 |
A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; M | 2000 |
Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; | 2000 |
[Sumatriptan nasal spray 20mg: efficacy, tolerance and quality of life in migraine patients].
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Migraine Dis | 2000 |
Naproxen sodium decreases migraine recurrence when administered with sumatriptan.
Topics: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug | 2000 |
Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Indoles; Middle Ag | 2000 |
One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study.
Topics: Administration, Intranasal; Adolescent; Child; Dose-Response Relationship, Drug; Female; Humans; Mal | 2000 |
Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; | 2000 |
Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine.
Topics: Acetaminophen; Adult; Analgesics; Antipyrine; Capsules; Chloral Hydrate; Double-Blind Method; Drug C | 2001 |
Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study.
Topics: Administration, Oral; Adult; Double-Blind Method; Female; Humans; International Cooperation; Male; M | 2001 |
A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aspirin; Double-Blind Method; Drug Therapy, Combinati | 1992 |
Sumatriptan and recurrence of migraine.
Topics: Double-Blind Method; Drug Administration Schedule; Humans; Indoles; Migraine Disorders; Recurrence; | 1992 |
Treatment of migraine attacks with sumatriptan.
Topics: Adolescent; Adult; Aged; Consumer Behavior; Double-Blind Method; Drug Tolerance; Female; Humans; Ind | 1991 |
Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group.
Topics: Adult; Aged; Consumer Behavior; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up | 1991 |
A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group.
Topics: Administration, Oral; Adult; Aged; Caffeine; Double-Blind Method; Drug Combinations; Electrocardiogr | 1991 |
Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group.
Topics: Adult; Aged; Consumer Behavior; Double-Blind Method; Female; Humans; Indoles; Injections, Subcutaneo | 1991 |
A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group.
Topics: Absorption; Administration, Intranasal; Adult; Disability Evaluation; Double-Blind Method; Female; H | 1991 |
Oral sumatriptan in acute migraine.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Double-Blind Method; Drug Evaluation; Female | 1991 |
33 other studies available for sumatriptan and Recrudescence
| Article | Year |
|---|---|
Activation of pain by sumatriptan.
Topics: Adult; Female; Humans; Inflammation; Injections, Subcutaneous; Male; Middle Aged; Pain; Prospective | 2003 |
[Strong and sustained-acting triptan. Therewith migraine does not return soon].
Topics: Administration, Oral; Clinical Trials as Topic; Humans; Indoles; Migraine Disorders; Placebos; Pyrro | 2003 |
Open label study of intranasal sumatriptan (Imigran) for footballer's headache.
Topics: Administration, Intranasal; Headache; Humans; Migraine Disorders; Migraine without Aura; Pain Measur | 2005 |
Change in frequency pattern in cluster headache induced by subcutaneous sumatriptan.
Topics: Cluster Headache; Humans; Injections, Subcutaneous; Recurrence; Serotonin Receptor Agonists; Sumatri | 2005 |
[Efficacy of sumamigren at early and late stages of migraine attack].
Topics: Adult; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Migraine Disorders | 2007 |
An adult case of cyclic vomiting syndrome successfully responding to valproic acid.
Topics: Anti-Anxiety Agents; Anticonvulsants; Antiemetics; Consciousness Disorders; Diazepam; Female; Humans | 2008 |
Recurrent depression after sumatriptan administration for treatment of migraine.
Topics: Depressive Disorder; Female; Humans; Middle Aged; Migraine Disorders; Recurrence; Sumatriptan | 1995 |
Subcutaneous sumatriptan in a clinical setting: the first 100 consecutive patients with acute migraine in a tertiary care center.
Topics: Acute Disease; Adolescent; Adult; Aged; Ambulatory Care Facilities; Female; Humans; Injections, Subc | 1994 |
Use of high sumatriptan dosages during episodic cluster headache: three clinical cases.
Topics: Adult; Cluster Headache; Humans; Injections, Subcutaneous; Male; Middle Aged; Recurrence; Serotonin | 1996 |
Sumatriptan in clinical practice: a 2-year review of 453 migraine patients.
Topics: Adult; Female; Humans; Male; Middle Aged; Migraine Disorders; Netherlands; Recurrence; Sumatriptan | 1996 |
How does sumatriptan perform in clinical practice?
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; In | 1995 |
[18 months long-term analysis of effectiveness, safety and tolerance of sumatriptan s.c. in acute therapy of migraine attacks].
Topics: Adult; Drug Tolerance; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Long-Term Care; | 1996 |
Headache recurrence.
Topics: Headache; Humans; Recurrence; Sumatriptan | 1996 |
Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients.
Topics: Adult; Female; Headache; Humans; Male; Middle Aged; Prognosis; Recurrence; Risk Factors; Sumatriptan | 1996 |
Sumatriptan in the treatment of cyclic vomiting.
Topics: Abdominal Pain; Adult; Humans; Male; Nausea; Recurrence; Serotonin Receptor Agonists; Sumatriptan; V | 1995 |
Sumatriptan treatment of acute migraine attacks in a Saudi population.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Dose-Response Relationship, Drug; Drug Monit | 1997 |
Would any acute treatment for migraine demonstrate recurrence?
Topics: Humans; Migraine Disorders; Oxazoles; Oxazolidinones; Recurrence; Serotonin Receptor Agonists; Sumat | 1997 |
Recurrent neck pain as a variant of migraine: description of four cases.
Topics: Adult; Carotid Arteries; Female; Humans; Magnetic Resonance Imaging; Migraine Disorders; Neck; Pain; | 1997 |
5-HT1B receptor polymorphism and clinical response to sumatriptan.
Topics: Adult; Aged; Alleles; Female; Gene Frequency; Humans; Male; Middle Aged; Migraine Disorders; Polymor | 1998 |
Successful treatment of headache related to intravenous immunoglobulin with antimigraine medications.
Topics: Adult; Analgesics, Non-Narcotic; Dihydroergotamine; Female; Headache; Humans; Immunoglobulins, Intra | 1998 |
Dosing of oral sumatriptan: a review of our first 104 patients.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Migraine D | 1998 |
Tolfenamic acid decreases migraine recurrence when used with sumatriptan.
Topics: Adult; Analgesics; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Migraine Disorders; | 1999 |
Issues relating to the assessment of migraine recurrence following triptan therapy.
Topics: Humans; Migraine Disorders; Recurrence; Serotonin Receptor Agonists; Sumatriptan | 1999 |
Migraine: which triptan?
Topics: Drug Administration Routes; Drug Costs; Family Practice; Humans; Migraine Disorders; Recurrence; Ser | 1999 |
Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Analgesics; Antiemetics; Calcium Channel Block | 1999 |
Patient-selected dosing in a six-month open-label study evaluating oral sumatriptan in the acute treatment of migraine. Sumatriptan Tablets S2CM10 Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Analgesia; Female; Humans; Male; Middl | 1999 |
Alteration in nature of cluster headache during subcutaneous administration of sumatriptan.
Topics: Adult; Chronic Disease; Cluster Headache; Headache; Humans; Injections, Subcutaneous; Male; Middle A | 2000 |
Zolmitriptan: new product. Similar to sumatriptan.
Topics: Clinical Trials as Topic; Drug Interactions; Humans; Migraine Disorders; Oxazoles; Placebos; Recurre | 1999 |
Clinical benefits of early triptan therapy for migraine.
Topics: Acute Disease; Dose-Response Relationship, Drug; Early Diagnosis; Humans; Migraine Disorders; Recurr | 2002 |
Sumatriptan, serotonin, migraine, and money.
Topics: Acute Disease; Costs and Cost Analysis; Humans; Indoles; Migraine Disorders; Recurrence; Serotonin; | 1992 |
Headache recurrence after subcutaneous sumatriptan.
Topics: Adult; Female; Humans; Indoles; Injections, Subcutaneous; Male; Middle Aged; Migraine Disorders; Rec | 1992 |
Headache recurrence after subcutaneous sumatriptan and early treatment.
Topics: Adult; Female; Headache; Humans; Indoles; Injections, Subcutaneous; Male; Middle Aged; Recurrence; S | 1992 |
Sumatriptan and recurrence of migraine.
Topics: Humans; Indoles; Migraine Disorders; Recurrence; Sulfonamides; Sumatriptan; Vasoconstrictor Agents | 1992 |